Holen Sie sich die Stockscreener-App
18.46
0.49%
0.09
Schlusskurs vom Vortag:
$18.37
Offen:
$18.37
24-Stunden-Volumen:
3.09M
Relative Volume:
1.04
Marktkapitalisierung:
$58.32B
Einnahmen:
$29.85B
Nettoeinkommen (Verlust:
$776.90M
KGV:
76.66
EPS:
0.2408
Netto-Cashflow:
$4.35B
1W Leistung:
+3.19%
1M Leistung:
+15.30%
6M Leistung:
+24.98%
1J Leistung:
+35.54%
1-Tages-Spanne:
$18.36
$18.50
1-Wochen-Bereich:
$17.58
$18.50
52-Wochen-Spanne:
$12.99
$18.50
Takeda Pharmaceutical Co Adr Stock (TAK) Company Profile
Compare TAK vs ZTS, HLN, TEVA, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
TAK
Takeda Pharmaceutical Co Adr
|
18.46 | 58.03B | 29.85B | 776.90M | 4.35B | 0.2408 |
|
ZTS
Zoetis Inc
|
126.65 | 55.37B | 9.40B | 2.65B | 2.24B | 5.935 |
|
HLN
Haleon Plc Adr
|
11.20 | 49.70B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
33.98 | 39.50B | 17.41B | 1.43B | 1.00B | 1.2182 |
|
UTHR
United Therapeutics Corp
|
473.66 | 20.50B | 3.13B | 1.27B | 1.12B | 26.39 |
Takeda Pharmaceutical Co Adr Stock (TAK) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-01-13 | Fortgesetzt | Morgan Stanley | Overweight |
| 2025-04-02 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-03-16 | Hochstufung | BofA Securities | Neutral → Buy |
| 2022-07-19 | Hochstufung | Cowen | Market Perform → Outperform |
| 2021-10-07 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-19 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-11-01 | Eingeleitet | Cowen | Market Perform |
| 2019-08-15 | Herabstufung | Daiwa Securities | Outperform → Neutral |
Alle ansehen
Takeda Pharmaceutical Co Adr Aktie (TAK) Neueste Nachrichten
Anti-Obesity Drugs Market to Reach US$195.99 Billion by 2036 as GLP-1 Therapies Drive a Structural Shift in Weight Management - GlobeNewswire Inc.
FedEx Upgraded, Costco Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Earnings call transcript: Takeda beats Q3 2025 forecasts, stock climbs - Investing.com
Takeda Pharmaceutical ADR: Defensive Pharma Giant Tests Investor Patience as Shares Drift Near Lows - AD HOC NEWS
Is Takeda Pharmaceutical Company Limited (TAK) One of the Best Healthcare Stocks to Buy for 2026? - Finviz
Argenx SE – ADR (ARGX) Sentiments Bolstered on Vyvgart FDA Priority Review Milestone - Yahoo Finance
Takeda Pharma ADR earnings beat by $0.04, revenue topped estimates - Investing.com Australia
Takeda Q3 FY2025 slides: Revenue dips 3.3% as company preps key 2026 launches - Investing.com
Earnings call transcript: Takeda Pharma Q3 2026 sees mixed performance - Investing.com
Apple, Visa, KLA-Tencor and more set to report earnings Thursday By Investing.com - Investing.com Nigeria
Takeda Pharmaceutical ADR Gets Technical Rating Upgrade - Investor's Business Daily
Biotech Stocks To Watch And Pharma Industry News - Investor's Business Daily
US earnings seasonQ4 2025 - Interactive Investor
ADMA Gains 13.8% in Three Months: More Upside Potential for 2026? - Finviz
KROS Stock Surges 85.6% in a Year: More Upside Potential in 2026? - Finviz
Takeda Pharmaceutical ADR Sees IBD RS Rating Climb To 76 - Investor's Business Daily
Book value per share of Takeda Pharmaceutical Co. Ltd. Sponsored ADR – GETTEX:TKDA - TradingView — Track All Markets
The Truth About Takeda Pharmaceutical Co Ltd: Is This Pharma Giant a Hidden Power Play for Your Port - AD HOC NEWS
G-Protein Coupled Receptors (GPCRs) Market Size to Hit USD 6.04 Billion by 2032, Growing at a CAGR of 5.59% - GlobeNewswire Inc.
Ethic Inc. Buys 43,295 Shares of Takeda Pharmaceutical Co. $TAK - Defense World
Takeda Pharmaceutical (NYSE:TAK) Strengthens Position in Healthcare - Kalkine Media
Takeda Pharmaceutical Co Ltd (TAK) Bonds - GuruFocus
Takeda Pharmaceutical Co Ltd ADR Stock Price Today | NYSE: TAK Live - Investing.com
Peptide Therapeutics Market Size to Reach USD 82.19 Billion by 2032; Surging Requirements for Targeted Medicines in Oncology Augment Market Expansion - GlobeNewswire Inc.
Denali Enters Into a $275M Funding Deal With Royalty Pharma - Finviz
INNOVENT BIO Completes Introduction of Takeda, Raising ~HKD780M Net - AASTOCKS.com
TAK vs. DSNKY: Which Stock Is the Better Value Option? - MSN
Eli Lilly Upgraded, Chewy Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Coca-Cola Upgraded, Boeing Downgraded: Updated Rankings on Top Blue-Chip Stocks - InvestorPlace
Finanzdaten der Takeda Pharmaceutical Co Adr-Aktie (TAK)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.80%
0.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):